Work

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.9532

Authors: Philip C. Mack, Mary Weber Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann C. Melnick, Zenta Walther, Fred R. Hirsch, Katerina A. Politi, Karen Kelly, David R. Gandara

Institutions: Icahn School of Medicine at Mount Sinai, Fred Hutch Cancer Center, SWOG Cancer Research Network, Yale University, UC Davis Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3031615570

Cites:

Cited by: 11

Related to: 10